TLX News: Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin - 18th Mar 2025, 9:52am

[annb0t]

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company's lead prostate cancer imaging agent. Illuccix® is the first and only PSMA-PET[1] prostate cancer imaging agent to ...

>>> Read more: Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America